Check-Cap

31 articles with Check-Cap

• 

  BioSpace Global Roundup, July 11

  7/11/2019

  Companies from across Europe, Asia and around the globe share pipeline and business updates.

• Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System

  7/9/2019

  Check-Cap Ltd., announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.

• 

  BioSpace Movers and Shakers, June 7

  6/7/2019

  Pharma and biotech companies strengthen their executive and leadership teams with new appointments.

• Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations

  6/3/2019

  Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics

• Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection

  5/16/2019

  Check-Cap Ltd. announced that it will present data at Digestive Disease Week 2019, to be held on May 18-21, 2019 in San Diego, California.

• Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®

  5/13/2019

  Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S.

• Check-Cap Reports First Quarter 2019 Financial Results

  5/13/2019

  Initiates U.S. pilot study of C-Scan® at NYU School of Medicine and Mayo Clinic

• Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening

  4/8/2019

  Check-Cap Ltd. today announced the initiation of its U.S. pilot study of the C-Scan® system, following Institutional Review Board approval and full Investigational Device Exemption application approval by the U.S. Food and Drug Administration.

• Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results

  3/28/2019

  Check-Cap is a clinical stage medical diagnostics company advancing the development of C-Scan®

• 

  BioSpace Movers and Shakers: March 22

  3/22/2019

  Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.

• Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®

  2/12/2019

  Check-Cap Ltd., announced it has received Institutional Review Board approval from New York University School of Medicine to initiate a U.S. pilot study of the C-Scan® system.

• Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering

  2/4/2019

  Check-Cap Ltd. today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit, in a registered direct offering.

• Check-Cap Announces FDA Conditional Approval of IDE to Initiate U.S. Pilot Study of C-Scan®

  12/13/2018

  Study to begin upon review and approval of Institutional Review Board (IRB)

• Check-Cap Reports Third Quarter 2018 Financial Results

  11/5/2018

  Announced Interim Results from Post-CE Approval Study of C-Scan®

• Check-Cap Announces IDE Submission to FDA for Its C-Scan® System

  10/9/2018

  If Approved, U.S. Pilot Study Anticipated to Commence in 4Q 2018

• Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System

  9/5/2018

  Check-Cap Ltd. today announced it has received approval from the Israeli Ministry of Health, the Medical Device Division (known as "AMAR"), to initiate commercial sales in Israel of the C-Scan system that received CE Mark approval in January 2018.

• Check-Cap Announces Promising Interim Results from its Ongoing Post-CE Approval Study of C-Scan® System Version 3

  9/4/2018

  Management to present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 5 at 3:00pm ET

• Check-Cap Reports Second Quarter 2018 Financial Results

  7/31/2018

  Check-Cap Ltd. announced financial results for the second quarter and six months ended June 30, 2018.

• Check-Cap Announces Publication of CE Mark Multicenter Clinical Study Results on C-Scan® in Gut

  5/22/2018

  Check-Cap Ltd. a clinical stage medical diagnostics company engaged in the development of C-Scan®, today announced that the results of its multicenter clinical study that examined C-Scan safety and efficacy (compared to FIT and colonoscopy) for polyp detection confirmed by ensuing colonoscopy.

• Check-Cap Regains Compliance With Nasdaq Minimum Bid Price Requirement

  4/19/2018

  Check-Cap Ltd. announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).